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Abstract
Background: The tumor suppressor protein phosphatase and tensin homolog (PTEN) is a key regulator of the PI3K/
AKT pathway which is frequently altered in a variety of tumors including a subset of acute B-lymphoblastic
leukemias (B-ALL). While PTEN mutations and deletions are rare in B-ALL, promoter hypermethylation and
posttranslational modifications are the main pathways of PTEN inactivation. Casein Kinase II (CK2) is often
upregulated in B-ALL and phosphorylates both PTEN and DNA methyltransferase 3A, resulting in increased PI3K/AKT
signaling and offering a potential mechanism for further regulation of tumor-related pathways.
Methods: Here, we evaluated the effects of CK2 inhibitor CX-4945 alone and in combination with hypomethylating
agent decitabine on B-ALL proliferation and PI3K/AKT pathway activation. We further investigated if CX-4945
intensified decitabine-induced hypomethylation and identified aberrantly methylated biological processes after CK2
inhibition. In vivo tumor cell proliferation in cell line and patient derived xenografts was assessed by longitudinal
full body bioluminescence imaging and peripheral blood flow cytometry of NSG mice.
Results: CX-4945 incubation resulted in CK2 inhibition and PI3K pathway downregulation thereby inducing
apoptosis and anti-proliferative effects. CX-4945 further affected methylation patterns of tumor-related transcription
factors and regulators of cellular metabolism. No overlap with decitabine-affected genes or processes was detected.
Decitabine alone revealed only modest anti-proliferative effects on B-ALL cell lines, however, if combined with CX-
4945 a synergistic inhibition was observed. In vivo assessment of CX-4945 in B-ALL cell line xenografts resulted in
delayed proliferation of B-ALL cells. Combination with DEC further decelerated B-ALL expansion significantly and
decreased infiltration in bone marrow and spleen. Effects in patient-derived xenografts all harboring a t(4;11)
translocation were heterogeneous.
Conclusions: We herein demonstrate the anti-leukemic potential of CX-4945 in synergy with decitabine in vitro as
well as in vivo identifying CK2 as a potentially targetable kinase in B-ALL.
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Background
In B cell acute lymphoblastic leukemia (B-ALL) distinct
molecular aberrations contribute to leukemogenesis in-
cluding mutations, chromosomal translocations or epi-
genetic dysregulation [1, 2]. The PI3K/AKT pathway
induces proliferation, inhibits apoptosis and is involved
in B-ALL pathogenesis suggesting potential therapeutic
targets [3]. PTEN antagonizes AKT phosphorylation and
subsequent pathway activation. As lately reviewed PTEN
phosphorylation is considered the most common way of
PTEN inactivation in B-ALL in contrast to mutations or
deletions in other types of leukemia and solid tumors [4,
5]. Increased phosphorylation of PTEN reduces its phos-
phatase activity resulting in anti-apoptotic downstream
signaling [6].
Apart from increased phosphorylation hypermethyl
ation-induced decreased PTEN transcription has been
reported in several tumors including B-ALL [7]. DNA
methyltransferase 3A (DNMT3A) overexpression leads
to PTEN promoter hypermethylation in chronic eo-
sinophilic leukemia cells [8]. Hypomethylating agents
(HMA) can restore the PTEN activity and inhibit
PI3K/AKT downstream signaling [8]. In B-ALL inacti-
vation of numerous tumor suppressor genes by aber-
rant methylation is associated with poor prognosis
[9]. Recently we demonstrated that HMA induce
apoptosis and cell cycle arrest and inhibit prolifera-
tion in human B-ALL [10].
Regulation of DNMT3A activity in B-ALL is not
well explored as in contrast to other hematological
neoplasms mutations do not seem to occur [11].
Deplus et al. reported that Casein Kinase II (CK2) is
able to phosphorylate DNMT3A in osteosarcoma cells
and thus mediate genomic methylation [12]. CK2 is a
highly conserved serine/threonine kinase frequently
overexpressed in solid and hematological neoplasms
including B-ALL [13]. CK2 phosphorylates a variety
of substrates across numerous pathways and cellular
functions. Among those are apoptosis, cell cycle regu-
lation, proliferation and transcription mediated via
Wnt, hedgehog, JAK/STAT and NFkB pathways [14].
CK2 further phosphorylates and therefore inactivates
tumor suppressor genes like IKZF1 and PTEN in
human leukemia cells [15, 16]. In B-ALL cells, Gomes
et al. demonstrated that CK2 inhibition by ATP-com-
petitive inhibitor CX-4945 rescued PTEN phosphatase
activity accompanied by apoptosis of B-ALL cells [6].
CK2 inhibition also restored IKZF1 tumor suppressor
function [15]. Several studies further demonstrated
anti-proliferative effects on solid and hematological
tumor entities in vitro and in vivo [17–19]. The
mechanisms behind CK2’s oncogenic effects and po-
tential therapeutic interventions are currently widely
discussed [20].
Here, we hypothesized that CK2 inhibitor CX-4945
alone and in combination with HMA decitabine (DEC)
reduces PTEN and AKT phosphorylation and thus in-
hibits PI3K/AKT mediated proliferation in vitro and in
vivo.
Methods
Cell lines and cell culture
Human B-ALL precursor cell lines SEM, RS4;11, REH
and NALM-6 were purchased from German Collection
of Microorganisms and Cell Cultures (DSMZ, Braun-
schweig, Germany) and cultured as recommended by
the manufacturer. Cell lines were selected in order to
compare inhibitors in a variety of cell lines of distinct
molecular and cytogenetic backgrounds to assess
whether inhibitory effects were more prominent in cer-
tain subtypes. Media were supplemented with 10%
heat-inactivated fetal calf serum (Biochrom, Berlin,
Germany) and 100 μg/ml penicillin and streptomycin
(Biochrom, Berlin, Germany) and cells were cultured at
37 °C and 5% CO2.
Inhibitory experiments
3.3 × 105 cells per ml were incubated with 5 μM
CX-4945 (Hycultec, Beutelsbach, Germany) or 0.1 μM
DEC (Selleckchem, Munich, Germany) dissolved in
DMSO or respective concentrations of DMSO (controls)
for up to 72 h. Apoptosis, proliferation and metabolic ac-
tivity were assessed as previously described [21]. Experi-
ments were carried out in biological triplicates. Results
are described as mean ± standard deviation. Significance
(p < 0.05) was estimated by 2-tailed student’s t test. Syn-
ergy of CX-4945 and DEC combination was calculated
by the Bliss independence model [22]. In this test, the
observed effect of a combinatory treatment is compared
to a calculated expected effect. The expected effect (E) is
calculated as follows: E = (A + B) − (A * B), where A and
B represent the relative inhibition of single agents A and
B. The difference between the observed and expected ef-
fect (Δ =O - E) of the combinatory treatment then de-
termines the level of synergy. If the observed inhibitory
effect is higher than the expected value (Δ > 0) the com-
bination is referred to as synergistic while Δ < 0 is con-
sidered antagonistic. For the calculation, mean values of
metabolic activity as well as proliferation after 48 h and
72 h incubation of three independent experiments were
used.
Protein analysis
Cells were lysed using RIPA buffer (Cell Signaling, Danvers,
MA, USA) and ultra sound exposure. Proteins were sepa-
rated on Midi gels (Bio-Rad, Munich, Germany), blotted
onto a PVDF membrane (Bio-Rad) using Trans-Blot®
Turbo™ Transfer System (Bio-Rad, 2.5 A, 25 V, 10min),
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blocked in LI-COR (Lincoln, NE, USA) blocking buffer and
detected via LI-COR Odyssey Imaging System and
Image Studio Lite software. Antibodies are listed in
Additional file 1: Table S1. For quantification, band
intensities were assessed using Image Studio Lite soft-
ware. Values were normalized to respective GAPDH
control bands run on each individual gel and ratios
between phosphorylated and total protein are given
below the images. Mean values and standard devia-
tions of three individual experiments were calculated
and displayed as bar charts.
Genome-wide methylation analysis
After CX-4945 and DEC combined incubation genomic
DNA was extracted and bisulfite treated using the
NucleoSpin® Tissue Kit (Macherey-Nagel, Dueren,
Germany) and peqGOLD Bisulfite Conversion Kit (VWR
Peqlab, Erlangen, Germany). The methylation status of
the LINE-1 retrotransposon is a marker for global methy-
lation [23]. LINE-1 Methylation specific qPCR (MsqPCR)
was carried out in a final volume of 25 μl containing 20 to
50 ng bisulfite treated DNA, Quantitect SYBR Green PCR
Master Mix (Qiagen, Hilden, Germany) and primers spe-
cific for either methylated or unmethylated DNA as fol-
lows: initial denaturation (15min, 95 °C) followed by 45
cycles of denaturation (15 s, 94 °C), annealing (30 s, 55 °C)
and elongation (30 s, 72 °C). Primer sequences are listed in
Additional file 2: Table S2.
Whole methylome analyses were carried out at the
Genomics & Proteomics Core Facility of the German
Cancer Research Center (Heidelberg, Germany) using
the Illumina Infinium MethylationEPIC BeadChip plat-
form. Raw and processed data can be retrieved from
Gene Expression Omnibus (GSE110454). Raw methy-
lome data was normalized using quantile normalization
[24] and summarized to calculate mean beta values [25].
Genes were considered hypomethylated based on a fold
change (FC) < 0.25 compared to controls. Gene enrich-
ment analysis was performed using the functional anno-
tation tool DAVID [26] as previously described [27].
Gene ontology (GO) terms annotated to at least two
genes and statistically over-represented within the hypo-
methylated gene set were evaluated by hyper-geometric
testing using the entire genome as a universe set and a
p-value threshold of 0.05. Heatmaps and Venn diagrams
were generated using the built-in functions in R [28] and
gene-GO term associations were visualized through
Chord plots using the GOplot package [29].
Patients
Mononuclear cells from bone marrow (BM) aspirates of
newly diagnosed ALL patients (Rostock University Medical
Center) were isolated using Biocoll separating solution
(Merck Millipore, Darmstadt, Germany) and previously
characterized on a molecular level using next-generation
sequencing (Cancer hotspot panel, Ion PGM System,
Thermo Fisher Scientific, Schwerte, Germany) according to
the manufacturer’s protocol [10]. All experiments were per-
formed in accordance to the Declaration of Helsinki and
the local ethical committee standards.
Animal studies
Stably GFP and enhanced firefly luciferase (ffLuc)
transduced SEM and RS4;11 cell lines were kindly pro-
vided by Prof. Irmela Jeremias (Helmholtz Center Mun-
ich, Germany). SEM and RS4;11 were stably transduced
with GFP and enhanced firefly luciferase (ffLuc) in the
pCDH-EF1-MCS-T2A-copGFP vector (System Biosci-
ences, Mountain View, CA, USA) using EcoRI and
BamHI. Lentivirus production and cell transduction
were carried out as described before [30].
NOD scid gamma mice (NOD.Cg-Prkdcscid Il2rgtm1Wjl/
SzJ, NSG, Charles River Laboratories, Sulzfeld, Germany)
were bred and housed under specific pathogen-free condi-
tions with access to water and standard chow ad libitum.
All experiments were carried out in a laboratory setting
and no intervention was performed within the animal
housing and breeding rooms. Study group sizes were ten
animals for cell line-derived in vivo studies based on bio-
metric Power calculation and at least two animals per
group for patient-derived (PDX) experiments [31]. Experi-
ments were approved by the review board of the federal
state Mecklenburg-Vorpommern, Germany (reference
number: LALLF MV/7221.3–1.1-002/15). Study endpoints
for all mice used are listed in Additional file 3 : Table S3
and Additional file 4 : Table S4.
Mice were i.v. injected with 2.5 × 106 cells (SEM-
GFP-ffLuc, RS4;11-GFP-ffLuc or de novo B-ALL cells).
Tumor cell engraftment was evaluated 7 days after injec-
tion via bioluminescence imaging (BLI) using the Night-
OWL LB 983 in vivo Imaging System (Berthold
Technologies, Bad Wildbach, Germany) and Indigo soft-
ware (Berthold Technologies, version 1.04). For detection
animals were intraperitoneally injected with 4.5mg
D-Luciferin (GOLDbiotechnology, St. Louis, MO, USA),
anesthetized with ketamine (75mg/kg) and xylazine (5
mg/kg) and imaged in dorsal and ventral position (60 s ex-
posure, 560 nm emission).
Therapeutic intervention and evaluation of induced
effects
Mice were randomized based on sex, weight (19.1 g – 32.4 g),
age (8–16weeks) and tumor cell engraftment on d7. CX-4945
was dissolved in 0.9% saline containing 5% DMSO. DEC was
dissolved in PBS. Animals were simultaneously treated with
either vehicle (isotonic saline supplemented with 5% DMSO)
or 50mg/kg i.p. CX-4945 twice daily d7–12 based on previous
dose finding studies. For combination studies 0.4mg/kg DEC
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was applied i.p. once daily d7-d10. Results were compared to
previously published DEC-treated animals [10]. Drug response
was analyzed by BLI and peripheral blood (PB) flow cytometry
(GFP+ or CD19-FITC+/CD45-PE+ (Becton Dickinson, Heidel-
berg, Germany)).
At d30 or when PB blast frequency reached 30%
(PDX) mice were euthanized by cervical dislocation and
leukemic blast frequency was analyzed in PB, BM and
spleen. Means and standard deviation of BLI and blast
frequency values of all mice of a study group were calcu-
lated. Student’s t-test was performed to compare study
groups and values < 0.05 were considered significant.
May-Grünwald Giemsa staining of PDX spleen cells was
carried out as previously described and evaluated by
EVOS xl core microscopy [21].
Results
CX-4945 affects CK2 activity, PI3K/AKT signaling and cell
biology parameters
SEM and RS4;11 cells were incubated with 5 μM
CX-4945 for up to 24 h. Quantification of western blot
signals revealed most prominent reductions of phos-
phorylation of CK2 target sites (pS/pTDXE) [32] after
2 h (SEM) and 24 h (RS4;11) (Fig. 1a). Simultaneous
analysis of PTEN, AKT and downstream signaling protein
4EBP1 also showed declined phosphorylation (Fig. 1b).
Compared to controls, proliferation and metabolic ac-
tivity were significantly decreased in SEM, RS4;11, REH
and NALM-6 after 72 h (p < 0.05) (Fig. 2a, b). Further,
incubation with CX-4945 induced apoptosis with stron-
gest effects in SEM and RS4;11 (Fig. 2c).
Combined inhibition of CK2 and DNMT3A increases
effects synergistically
As CK2 is known to influence DNA methylation via
DNMT3A phosphorylation CX-4945 was combined
with DEC (0.1 μM) for up to 72 h. In DEC-sensitive
cell lines SEM and NALM-6 simultaneous application
of DEC and CX-4945 significantly reduced the meta-
bolic activity to 33.6 and 33.5%, respectively com-
pared to mono applications (Fig. 3a). The CX-4945
mono application-induced anti-metabolic effect was
highest in DEC-resistant RS4;11 cells (37.8%) but
addition of DEC did not further decrease metabolic
activity. Potential synergistic effects of combined CK2
inhibition and HMA exposure were calculated with
Bliss values above 0 indicating synergy. After 72 h,
combined application of CX-4945 and DEC demon-
strated synergistically reduced metabolic activity in
SEM (0.194) and NALM-6 (0.240) but not in RS4;11
(− 0.027) cells. In contrast, no synergistic effect was
detected analyzing proliferation. Similar results were
obtained after 48 h of incubation (data not shown).
Synergistic effects are not evoked via PI3K/AKT signaling
or intensified hypomethylation
Western blot analyses were performed to evaluate whether
addition of DEC to CX-4945 would further influence PI3K/
AKT signaling. While DEC alone had hardly any effect on
protein phosphorylation combination of DEC and CX-4945
evoked results similar to CX-4945 alone (Fig. 3b). No add-
itional PI3K or MAP kinase pathway regulation was ob-
served (data not shown).
Fig. 1 Effects of CX-4945 on CK2 activity and PI3K/AKT pathway phosphorylation in B-ALL cell lines. a CK2 activity in SEM and RS4;11 cells was
assessed by western blot analysis of phosphorylated CK2 target sites following 2 h (SEM) or 24 h (RS4;11) incubation with CX-4945 (5 μM) (lower
panel). For quantification Image Studio Lite software (Version 5.2) was used to determine signal intensities of phosphorylated CK2 target sites and
total CK2 alpha 1 protein. Protein bands were normalized to the GAPDH band of the respective sample and the ratio of phosphorylated targets
to total CK2A1 protein signal intensities was calculated. Means and SD of three independent experiments are depicted as bar charts in the upper
panel. Individual ratios of one representative blot are stated below the respective bands. b Activity of PTEN, AKT and 4EBP1 proteins was analyzed
by western blot of phosphorylated and total protein forms after 2 h (SEM) or 24 h (RS4;11) incubation with 5 μM CX-4945 (mean + SD; n = 3)
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Changes in global methylation were assessed by LINE-1
retrotransposon MsqPCR and revealed no hypomethylating
effect of CX-4945 (Additional file 5: Figure S1). To evaluate
whether the observed synergistic anti-proliferative effect
was evoked by potential gene-specific hypomethylation of
tumor suppressor genes or signaling proteins genome-wide
methylome analysis was performed. Compared to controls
DEC reduced methylation of 1578 genes while the combin-
ation of both drugs induced hypomethylation in 927 genes
(FC < 0.25). After CX-4945 incubation 54 genes were
hypomethylated (Fig. 4a, Additional file 6: Table S5 and
Additional file 7: Tables S6). Methylation of only 5 genes
(BDNFOS, ZCCHC4, ABT1, BACH2, UBN1) was reduced
by both mono applications as well as combined incubation.
Among these were transcription factors ABT1 (activator of
basal transcription 1) and BACH2 (basic leucine zipper
transcription factor). CX-4945-hypomethylated genes
mainly affected cellular process regulation, maturation
and metabolism (Fig. 4b, c; Additional file 8: Table S7).
The GO terms associated to genes regulated by com-
bined CK2 inhibition and DEC exposure were chroma-
tin modification and methylation (Additional file 9:
Figure S2, Additional file 10: Table S8). Interestingly,
there was marginal overlap between CX-4945, DEC or
combined therapy affected processes (Fig. 4c) and none
of the drugs changed the promoter methylation pattern
of PTEN or CK2 (Additional file 11: Table S9).
Inhibition of CK2 alone and in combination with DEC
delays tumor cell proliferation in vivo
The anti-leukemic activity of CX-4945 was investigated
in vivo using orthotopic SEM-GFP-ffLuc- and RS4;11-
GFP-ffLuc-derivded xenograft mouse models. These
t(4;11)-harbouring cell lines were selected based on most
promising results in vitro. Only healthy, age-, weight-,
sex- and engraftment-matched animals were included in
study groups. Therapeutic response was analyzed using
longitudinal full body BLI and flow cytometric detection
of GFP expression in PB, spleen and BM (Fig. 5). BLI
signals directly correlate to the number of luciferase+
tumor blasts and are therefore used as a direct marker
for tumor cell proliferation.
In SEM-derived xenografts CX-4945 delayed B-ALL cell
proliferation until day 24 (CX-4945 4.3 ± 2.2 × 109 ph/s;
control 5.5 ± 0.8 × 109 ph/s) before reaching BLI signal
levels similar to the controls on day 30. Animals also
showed reduced PB blast counts throughout the entire
examination period (d30, CX-4945 12.9 ± 7.2%; control
20.6 ± 9.5%). DEC alone induced stronger effects than
CX-4945 mono therapy with significantly decreased BLI
signals (d24, 2.1 ± 1.5 × 109 ph/s) as well as PB, spleen and
BM blast frequencies (Fig. 5b). Combined CX-4945
and DEC therapy was more effective than DEC alone
and significantly decreased bioluminescence signals
and blast frequency compared to CX-4945 mono ap-
plication (d24, 1.3 ± 1.3 × 109 ph/s). Further, leukemic
infiltration of BM and spleen was significantly re-
duced compared to controls.
CX-4945 had no influence on RS4;11-derived xeno-
grafts (Fig. 5b). Addition of DEC resulted in significantly
reduced B-ALL cell proliferation indicated by delayed
BLI signal increase (d30, control 4.7 ± 0.4 × 109 ph/s;
Fig. 2 Biological effects of CK2 inhibition on B-ALL cell lines. a
Proliferation was determined using trypan blue staining after 72 h
incubation of increasing CX-4945 concentrations and compared to
control cells set to 100% (mean + SD; n ≥ 2; * p < 0.05, ** p < 0.01,
*** p < 0.005 for n ≥ 3 experiments). b The WST-1 assay was used to
evaluate metabolic activity after 72 h incubation of increasing
concentrations of CX-4945. Three technical replicates were
performed for each sample (mean + SD; n ≥ 3; * p < 0.05, ** p < 0.01,
*** p < 0.005). c The effect on apoptosis was measured by Annexin
V-FITC/PI following 72 h CX-4945 incubation. Early apoptotic cells
(Annexin V+/PI−) are located in the lower right quadrant while late
apoptotic and necrotic cells (Annexin V+/PI+) are located in the
upper right part. (n≥ 2)
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CX-4945 4.8 ± 0.6 × 109 ph/s; DEC 1.8 ± 0.2 × 109 ph/s;
CX + DEC 1.4 ± 0.5 × 109 ph/s) as well as PB, BM and
spleen blast counts.
CX-4945 in combination with DEC influences patient-
derived B-ALL cell proliferation in vivo
To increase comparability of animal studies and human
leukemia patients, xenografts of three B-ALL patients
were established in NSG mice and treated with
CX-4945, DEC or in combination until control animals
reached a PB blast amount of 30%. To ensure compar-
ability between cell line- and patient-derived xeno-
grafts, only MLL-rearranged samples were engrafted.
Treatment with CX-4945 did not decrease leukemic
blasts in BM, spleen or PB in PDX mice (Fig. 6a).
Combination with DEC as well as DEC incubation
alone resulted in a strong reduction of tumor load in
patient 0152-derived mice. Interestingly, basal AKT
activity in spleen cells was reduced in patient 0152
xenografts compared to other PDX samples (Fig. 6b).
Phosphorylation of PTEN and other PI3K pathway
molecules was similar in all samples (data not
shown). Cytospin preparations of spleen cells revealed
no changes in blast morphology after CX-4945 or
combined therapy (Fig. 6c, inset). However, PB blast
frequency was decreased combinatory treatment (con-
trol 36.0%; CX + DEC 2.0%) (Fig. 6a).
In patient 0159-derived mice combined application of
CX-4945 and DEC lowered spleen infiltration while the
tumor burden in BM and PB remained constant. Only
minor changes in leukemic blast frequency were ob-
served in animals bearing patient 0122-derived tumors.
Discussion
In addition to mutations and structural changes of DNA
several mechanisms and pathways are involved in B-ALL
pathogenesis including posttranslational modifications
and aberrant methylation. Thus combined targeting of
tumor-initiating pathways is advantageous and currently
evaluated in a variety of approaches in preclinical and
clinical settings. Although CK2 inhibition and hypome-
thylation of tumor suppressor gene promoters show
promising results in hematological neoplasms the effect
of their combined application has not yet been ad-
dressed. Simultaneous CK2 inactivation and hypomethy-
lation may shed light on potential crosstalk between
both mechanisms and potential synergistic anti-prolifer-
ative effects on B-ALL cells.
In B-ALL increased promoter hypermethylation is a
typical feature observed in relapse, often silencing tumor
suppressor genes such as PTEN [5, 33]. PTEN is further
inhibited by CK2-mediated phosphorylation. CK2 is fre-
quently upregulated in hematological neoplasms and a
key regulator of diverse cellular mechanisms including
cell cycle, apoptosis and transcription [14, 34, 35].
In our study we found that CX-4945 inhibits CK2
resulting in decreased phosphorylation of PI3K pathway
signaling proteins and subsequent reduction of B-ALL cell
proliferation and metabolic activity as well as increased
apoptosis rates. Other studies of CK2 inhibition on B-ALL
cell lines also found PI3K pathway downregulation and re-
duced cell viability accompanied by apoptosis induction
[6, 15, 36, 37]. Methylome analysis also revealed a strong
influence of CX-4945 on the methylation of metabolism-
related genes, matching the data obtained by WST-1
Fig. 3 Effects of combined CK2 and DNMT3A inhibition in B-ALL cell lines. a The WST-1 metabolism assay was used to evaluate metabolic activity
after 72 h incubation of CX-4945 (5 μM) and/or DEC (0.1 μM). Metabolic activity of control cells was set to 100%. Three technical replicates were
performed for each sample (mean + SD; n≥ 3; * p < 0.05, ** p < 0.01, *** p < 0.005). b Phosphorylation of PI3K/AKT pathway proteins was assessed by
western blot analysis and subsequent quantification of bands as described before. For protein activity assessment the ratio between phosphorylated
and total protein form was calculated and compared to control cells set to 100%. For CK2, phosphorylation of CK2 target sites was determined and
compared to the total form of CK2 alpha (mean + SD after 24 h (SEM) or 2 h (RS4;11) incubation with 5 μM CX-4945 and/or 0.1 μM DEC; n = 3)
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metabolic activity assay. Results within an in vivo human
B-ALL xenograft model matched in vitro anti-proliferative
results. Bioluminescence imaging also revealed delayed
leukemic proliferation and reduced blast frequency in
SEM-derived mice. Whether these effects were due to
cytotoxicity or due to cell death induction has to be
determined in further experiments. Matching our in
vitro data Song et al. demonstrated reduced leukemic
progression and an improved overall survival in a
NALM-6-derived xenograft model after 10 days of
treatment using higher concentrations than in our
study [15]. Other groups also discovered anti-prolifer-
ative potential of CK2 inhibition in CLL [38, 39] and
T-ALL in vivo studies [40].
We then added DEC to CX-4945 treatment in order
to identify potential enhanced pathway and methy-
lome modulation. We found that combined applica-
tion of CX-4945 and DEC acted synergistically in
vitro but while PI3K pathway phosphorylation mirrors
CX-4945 mono treatment, methylome patterns of
combined application show no overlap with either
single application. This suggests that a previously un-
considered mechanism is responsible for the observed
synergistic anti-proliferative effects. We hypothesized
that hypomethylation and thus activation of PTEN
might be responsible for decreased proliferation and
metabolic activity but could not detect significantly
lower methylation or phosphorylation after combined
Fig. 4 Methylome analysis of SEM cells. a The Venn diagram shows the number of hypomethylated genes after 48 h incubation with
5 μM CX-4945, 0.1 μM DEC or both compared to DMSO. Methylation data was normalized using quantile normalization and only changes
in methylation of at least 4-fold were considered relevant. b Hypomethylated genes were assigned to Gene Ontology (GO) Terms. The
chord plot shows the association between the top 7 enriched GO terms and top 30 hypomethylated genes. Genes were further classified
by their fold change compared to control cells (blue rectangle). CX-4945 incubation mainly influenced genes annotated by GO terms
relating to metabolic processes. FBXO5 and RPS6KA2 have an association to all seven selected GO terms. c Average linking hierarchical
clustering of the top-10 regulated biological processes of each treatment was performed and visualized in a heatmap based on statistical
significance (−10log p-values)
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therapy. However, the transcription factor BACH2 is
a potential linker between CX-4945 and DEC-induced
effects. We found that BACH2 is hypomethylated by
CX-4945, DEC and combined treatment while Ando
et al. demonstrated that it can be phosphorylated by
PI3K pathway proteins [41]. Regulating B cell devel-
opment at the pre-B cell receptor checkpoint BACH2
functions as a tumor suppressor in B-ALL [42–44].
Further, Ge et al. recently demonstrated that both
BACH2 and its counterpart BCL6 interact with CK2
target Ikaros (IKZF1) resulting in increased BACH2
expression and reduced B-ALL proliferation [45]. Epi-
genetic modulation of the BACH2/BCL6 axis may
therefore be an additional mechanism to regulate
tumor cell apoptosis and proliferation. However, the
importance of CX-4945-mediated loss of CK2 kinase
activity for the observed effects is not yet clear as
DEC mono therapy was not significantly inferior to
combined CX-4945 and DEC treatment during the obser-
vation period in vivo. Prolonged therapeutic intervention
or higher CX-4945 doses might be beneficial for the treat-
ment outcome as stated above. It further seems possible
that, although no significant synergistic anti-proliferative
effect was observed, CX-4945 alone or in combination
with DEC influences biochemical, metabolic or other sig-
naling pathways in tumor blasts.
As the PI3K/AKT signaling pathway can be aberrantly
activated in B-ALL patients we further tested CX-4945
in three B-ALL patient-derived xenograft models all har-
boring a t(4;11) translocation [6. Independently of pa-
tients’ PTEN and AKT phosphorylation status or
hotspot mutations no satisfactory anti-leukemic effect
was achieved. This matches the findings of Prins et al.
who incubated 56 primary pediatric and adult B-ALL
samples with increasing concentrations of CX-4945 and
found reduced tumor cell viability in only 3 (5.2%)
Fig. 5 In vivo evaluation of CX-4945 and DEC. a Longitudinal observation of leukemic blast proliferation in four representative SEM-ffluc xenograft
mice is displayed following vehicle (NaCl supplemented with 5% DMSO, BID d7–12), CX-4945 (50mg/kg body weight (BW), BID d7–12), DEC (0.4mg/
kg BW, d7–10) or CX-4945 plus DEC treatment over a period of 30 days. Increasing luminescence (ph/s) is proportional to proliferation of luciferase-
expressing SEM-ffluc cells. b Quantification of full body bioluminescence (ph/s) after treatment in SEM-ffluc and RS4;11-ffluc animals was performed by
adding total luminescence signals of dorsal and ventral imaging. Significant differences are indicated for combined treatment of CX-4945 and DEC vs
CX-4945 mono application. CX-4945 alone induced no significant change in full body bioluminescence compared to controls (mean + SD; * p < 0.05,
** p < 0.01, *** p < 0.005). Blast frequency in PB was assessed by flow cytometry measurement of GFP+ SEM-ffluc and GFP+ RS4;11-ffluc cells over a
period of 30 days. Significant differences are indicated for combined therapy vs CX-4945 mono application (mean + SD; * p < 0.05, *** p < 0.005).
Infiltration of leukemic blasts was analyzed in BM and spleen after euthanasia on day 30. The amount of GFP+ SEM-ffluc and RS4;11-ffluc blasts was
determined by flow cytometry (mean + SD; * p < 0.05, *** p < 0.005)
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samples compared to much higher response rates in
T-ALL, CLL and lymphoma [38, 46]. In contrast Song et
al. found a reduced number of blasts following CX-4945
therapy in high risk B-ALL xenografts. [15] This discrep-
ancy might be explained by the fact that only patients
with a t(4;11) were examined or by different applica-
tion schemes. While Song et al. treated mice with
100 mg/kg daily for 22 days and analyzed organs dir-
ectly after the last application we used a shorter ap-
plication regime (50 mg/kg twice daily for 6 days) and
evaluated the blast frequency after 30 days or more. It
thus appears that CX-4945 delays leukemic blast pro-
liferation during therapy while this effect diminishes
when the drug is removed. This hypothesis also
matches our findings from cell line-derived B-ALL
xenograft observations. Evaluation of pharmacokinetic
parameters demonstrated long half-life of CX-4945 in
rats (14.7 h and 10.9 h for intravenous and oral ad-
ministration, respectively) [47] while Siddiqui-Jain et
al. found high clearance rates accompanied by rapidly
decreasing plasma concentrations in mice [48]. Fur-
ther pharmacokinetic evaluation is therefore neces-
sary. Alternative application schemes might be
beneficial and should be addressed in future studies.
Conclusion
Taken together we herein demonstrate that the novel
strategy of combined CK2 inhibition and DEC applica-
tion significantly decreases B-ALL proliferation. In this
study we evaluated PI3K/AKT signaling, methylome
patterns and therapeutic response in vivo after single
and combined application. Although CK2 is known to
interact with both, PI3K/AKT and DNMT3A-mediated
methylation neither pathway can be made fully respon-
sible for the observed synergistic effects [12]. Therefore,
further experiments need to be conducted to identify the
underlying mechanism of the demonstrated synergistic
anti-tumor potential.
Fig. 6 Evaluation of CX-4945 and DEC in patient-derived xenograft mice. a Xenograft mice of three different B-ALL patients (0122, 0152,
0159; patient characteristics were reported previously) were treated with vehicle (NaCl supplemented with 5% DMSO; BID d7–12), CX-4945
(50 mg/kg BW, BID, d7–12) or CX-4945 plus DEC (0.4 mg/kg BW, d7–10) and euthanized when PB blast frequency in controls reached
25%. The amount of patient-derived B-ALL tumor cells in BM, spleen and PB was assessed by CD45-FITC/CD19-PE staining and
subsequent flow cytometry (mean + SD; vehicle: n = 4–5 animals per patient, treatment groups: n = 1–2 animals per patient). b AKT and
PTEN activity status was analyzed in PDX mice spleen cells by western blot of phosphorylated and total protein forms. c Cytospin
preparations of cells isolated from spleens of patient 0152 derived mice. Slides were stained with Pappenheim and evaluated using the
EVOS xl core microscope and 100x magnification)
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